Atlas Trials

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Clinical trial NCT02891603 · COMPLETED

Trial details

NCT number
NCT02891603
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Graft Vs Host DiseaseGVHD
Start date
2017-06-08
Primary completion
2022-01-28
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.